Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation
Open Access
- 10 July 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 81 (3) , 774-790
Abstract
Background and Aims: Inflammatory response is crucial for bile acid (BA)-induced cholestatic liver injury, but molecular mechanisms remain to be elucidated. Solute Carrier Family 35 Member C1 (SLC35C1) can transport Guanosine diphosphate-fucose into the Golgi to facilitate protein glycosylation. Its mutation leads to the deficiency of leukocyte adhesion and enhances inflammation in humans. However, little is known about its role in liver diseases. Approach and Results: Hepatic SLC35C1 mRNA transcripts and protein expression were significantly increased in patients with obstructive cholestasis and mouse models of cholestasis. Immunofluorescence revealed that the upregulated SLC35C1 expression mainly occurred in hepatocytes. Liver-specific ablation of Slc35c1 (Slc35c1 cKO) significantly aggravated liver injury in mouse models of cholestasis induced by bile duct ligation and 1% cholic acid–feeding, evidenced by increased liver necrosis, inflammation, fibrosis, and bile ductular proliferation. The Slc35c1 cKO increased hepatic chemokine Ccl2 and Cxcl2 expression and T cell, neutrophil, and F4/80 macrophage infiltration but did not affect the levels of serum and liver BA in mouse models of cholestasis. Liquid chromatography with tandem mass spectrometry analysis revealed that hepatic Slc35c1 deficiency substantially reduced the fucosylation of cell-cell adhesion protein CEACAM1 at N153. Mechanistically, cholestatic levels of conjugated BAs stimulated SLC35C1 expression by activating the STAT3 signaling to facilitate CEACAM1 fucosylation at N153, and deficiency in the fucosylation of CEACAM1 at N135 enhanced the BA-stimulated CCL2 and CXCL2 mRNA expression in primary mouse hepatocytes and Primary Liver Carcinoma/Poliomyelitis Research Foundation/5-ASBT cells. Conclusions: Elevated hepatic SLC35C1 expression attenuates cholestatic liver injury by enhancing CEACAM1 fucosylation to suppress CCL2 and CXCL2 expression and liver inflammation.Keywords
This publication has 44 references indexed in Scilit:
- A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasisJournal of Hepatology, 2023
- Organic Anion Transporting Polypeptide (OATP) 1B3 is a Significant Transporter for Hepatic Uptake of Conjugated Bile Acids in HumansCellular and Molecular Gastroenterology and Hepatology, 2023
- Endoplasmic reticulum stress promotes sepsis‐induced muscle atrophy via activation of STAT3 and Smad3Journal of Cellular Physiology, 2023
- A novel role for interleukin 32 in cholestasisClinical and Translational Medicine, 2021
- Limb expression 1-like (LIX1L) protein promotes cholestatic liver injury by regulating bile acid metabolismJournal of Hepatology, 2021
- Carcinoembryonic antigen (CEACAM) family members and Inflammatory Bowel DiseaseCytokine & Growth Factor Reviews, 2019
- Carcinoembryonic antigen‐related cell adhesion molecule 1 controls IL‐2‐dependent regulatory T‐cell induction in immune‐mediated hepatitis in miceHepatology, 2018
- Chemokine–Chemokine Receptor CCL2–CCR2 and CX3CL1–CX3CR1 Axis May Play a Role in the Aggravated Inflammation in Primary Biliary CirrhosisDigestive Diseases and Sciences, 2013
- Roles of the nucleotide sugar transporters (SLC35 family) in health and diseaseMolecular Aspects of Medicine, 2013
- Loss of carcinoembryonic antigen‐related cell adhesion molecule 1 expression is an adverse prognostic factor in hepatocellular carcinomaCancer, 2005